Cytek Biosciences, INC 10-Q quarterly reports

Cytek Biosciences announced a 6% increase in total revenue for both the three and six-month periods ending June 30, 2026, reaching $48.1 million and $92.3 million respectively, though net losses also widened.

Cytek Biosciences reported Q1 2026 revenue of $44.1 million, a 6% year-over-year increase, alongside a net loss of $18.9 million.

Cytek Biosciences reported a net loss of $5.5 million for the third quarter of 2025, driven by increased operating expenses and a decline in product revenue, despite growth in service revenue.

Cytek Biosciences reported a 5% decrease in total revenue and an increased net loss for the first six months of 2025, alongside identified material weaknesses in internal controls.

Cytek Biosciences' Q1 2025 results reveal a revenue decrease, attributed to lower product sales, while the company continues to invest in research and development and commercial infrastructure.

Cytek Biosciences' Q3 2024 results show a slight revenue increase and a return to profitability, balanced against ongoing challenges in product sales and internal control weaknesses.

Cytek Biosciences experienced a decrease in product revenue but an increase in service revenue in the second quarter of 2024, resulting in a mixed financial performance.

Cytek Biosciences saw a 21% increase in revenue in the first quarter of 2024, driven by both product and service growth, though the company still reported a net loss.